Document › Details

Life Technologies Corporation. (2/18/10). "Press Release: Life Technologies’ SOLiD System Used in Research on Cancer, Human Genetic Variation". Carlsbad, CA.

Region Region Sub-Saharan Africa
Organisations Organisation Life Technologies Corporation (Nasdaq: LIFE)
  Group Life Technologies (Group)
  Organisation 2 Johns Hopkins University
Products Product SOLiD™ system (product series)
  Product 2 DNA sequencing
Index terms Index term solid tumour
  Index term 2 genome sequencing
Persons Person Gibbs, Richard (Baylor College 1996–200910– Director HGSC + SeqWright co-founder)
  Person 2 Miller, Kip (Life Technologies 200904 President Genetic Systems Division before Invitrogen)
     
Scientific Papers Highlight Use of Company's Next-Generation Sequencing Platform as Key Tool for Better Understanding of Human Origins and Disease

LifeTechnologies Corporation (NASDAQ:LIFE) today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD(TM) System was used in both of these research studies.

A paper in the journal Science Translational Medicine specifies that researchers demonstrated the application of next-generation sequencing to identify chromosomal abnormalities in solid tumors such as breast and colorectal cancer. The discovery, made by authors from the Johns Hopkins Kimmel Cancer Center and Life Technologies, demonstrates the potential to identify individual-specific biomarkers that may be useful to researchers in their development of future diagnostic products to monitor disease progression and tumor response to therapy. Entitled "Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing," the paper will appear in the February 24 edition of the journal.

Researchers used the SOLiD System to sequence DNA from six different tumor samples, two breast tumor samples and four colorectal tumor samples, along with matched normal tissue samples. They identified an average of nine different chromosomal abnormalities in each tumor sample that were not present in normal tissue, and these chromosomal abnormalities could be readily detected using polymerase chain reaction (PCR) in patient plasma samples.

In a separate paper, published in the February 18 edition of the journal Nature and titled "Complete Khoisan and Bantu Genomes from Southern Africa," scientists from a consortium of institutions that included Baylor College of Medicine and University of Pennsylvania performed sequence analysis on individuals descended from specific hunter-gatherer tribes of southern Africa, the oldest known lineage of modern humans. Included in this research was the sequencing of Nobel Peace Prize winner Archbishop Desmond Tutu's genome, using the SOLiD System. Archbishop Tutu's genome represents a mixture of southern African tribes and was compared to the hunter-gathers to better understand human diversity on a genetic level.

The study identified 1.3 million genetic variants that had not been previously observed, demonstrating that southern Africans are genetically quite distinct from Europeans, Asians and West Africans. In addition, it was shown that even within the hunter-gather tribes, more genetic diversity exists between these individuals than between Caucasians and Asians. As the genomes sequenced represent the first sequences of people from southern Africa, the data will contribute to the community's understanding of how rare genetic variations in southern Africans, and consequently other global populations, contribute to disease and possible treatments.

"Whole Human genome sequencing is clearly demonstrating its utility for unlocking the secrets to human diversity," said Richard Gibbs, Ph.D., Director of the Human Genome Sequencing Center at Baylor College of Medicine and an author on the Nature paper. "The speed and economics of current technologies are allowing scientists to amass data that gives us a broad understanding of both individual and rare genetic variations that impact human physiology and the development of diseases."

The SOLiD System is used by researchers globally in experiments to better understand the genetic nature of diseases such as cancer, diabetes, neurological disorders and other diseases. Its throughput, accuracy, speed and flexibility allow researchers to generate the data they need for their experiments and is contributing to the utility of sequencing as a potential clinical tool. Currently, the SOLiD System is for research use only, and is not intended for use in any diagnostic procedures.

"Technologies such as SOLiD are transforming how DNA sequencing is contributing to a more comprehensive understanding of human health," said Kip Miller, President of the Genetic Systems Division for Life Technologies. "The affordability and accuracy of the SOLiD System has made genome-wide sequencing a commonplace tool for scientists, and it has a real potential to become an integral part of genomic-based health decisions."

To read the complete Nature paper, please visit http://www.nature.com/nature/journal/v463/n7283/full/nature08795.html

About Life Technologies (http://www.lifetech.com)

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

LifeTechnologies Corporation
Patty Zamora,
760-476-7818
patty.zamora@lifetech.com

   
Record changed: 2010-07-21

More documents for Life Technologies (Group)

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
» top